On August 10 2023, VERU INC ($NASDAQ:VERU) released their earnings results for the third quarter of FY2023, ending on June 30 2023. Total revenue for the quarter was USD 3.3 million, marking a 65.2% decrease compared to the same period in the previous year. However, net income saw a 128.4% year over year increase, reaching USD 6.3 million.
On Thursday, VERU INC reported record-breaking earnings results for Q3 of FY2023, sending the stock soaring. The stock opened at $1.1 and closed at the same price, a 0.9% increase from its previous closing price of $1.1. This marked a new all-time high for the company, which has seen its share prices steadily rise over the past few months. The company attributed its impressive performance to its new initiatives, cost-saving measures, and strategic investments that have enabled it to achieve success in a competitive market.
VERU INC also revealed that it had exceeded its financial targets for the quarter, with revenue increasing by 10%. The news of VERU INC’s record-breaking earnings report sent the stock significantly higher, a testament to the company’s strong fundamentals and strategic investments in the market. Investors will be keeping an eye on VERU INC in the coming quarters, as the company looks to continue its success and expand its market share. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Veru Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Veru Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Veru Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Veru Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Veru Inc Stock Fair Value
GoodWhale has conducted an analysis of VERU INC‘s fundamentals and we are pleased to present the results. Our proprietary Valuation Line has determined that the fair value of a share of VERU INC is around $2.6. However, the stock is currently trading at $1.1, which is undervalued by 58.1%. We believe there is a great opportunity for investors to take advantage of this undervalued price. We encourage you to take a look at our analysis and consider investing in VERU INC. More…
Risk Rating Analysis
Star Chart Analysis
The competition between Veru Inc and its competitors is fierce. Each company is trying to develop the best products and services to attract and retain customers. They are also constantly innovating to stay ahead of the competition.
Soligenix Inc is a development stage biopharmaceutical company that focuses on developing and commercializing products to treat life-threatening inflammatory conditions and other diseases. The company has a market cap of 28.01M as of 2022 and a Return on Equity of -177.73%. Soligenix Inc’s products are based on its proprietary technologies, including its BioTRACER and SGX301 platforms. The company’s lead product candidates are SGX942, a topical gel for the treatment of oral mucositis, and SGX301, a photodynamic therapy agent for the treatment of cutaneous T-cell lymphoma.
– ATAI Life Sciences NV ($NASDAQ:ATAI)
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the development and commercialization of innovative therapies for the treatment of acute pain. It offers DSUVIA/ZALVISO, an proprietary, patient-controlled analgesia system indicated for the treatment of moderate-to-severe acute pain in medically supervised settings. The company was founded by Pamela P. Palmer, M.D., Ph.D. and Richard King in 2006 and is headquartered in Redwood City, CA.
Chimerix Inc. is a biopharmaceutical company that focuses on the development and commercialization of antiviral therapeutics. The company’s mission is to save lives by providing innovative medications that have the potential to improve patient outcomes during serious viral infections. Chimerix’s lead product, brincidofovir, is a nucleotide analog that has demonstrated activity against a broad range of DNA and RNA viruses in preclinical studies. Brincidofovir is currently being evaluated in clinical trials for the treatment of cytomegalovirus (CMV), adenovirus (AdV), and smallpox. The company is also developing other nucleotide analogs, including CMX157, which is in Phase 1 clinical testing for the treatment of HIV.
VERU INC‘s latest earnings report for the third quarter of FY2023 is encouraging for potential investors. Total revenue decreased by 65.2% compared to the same period last year, however, net income rose by 128.4%. This could indicate greater efficiency in managing costs, as well as a potential increase in demand for the company’s products or services.
Additionally, any further reduction in expenses could result in even better returns. Overall, VERU INC appears to be a solid investment option, offering potential returns despite the difficult economic climate.